Source: Annual Congress 2004 - Thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Antoniou, G. Pavlakou, T. Gregoratou, C. Papageorgiou, E. Chondrou, F. Dariotaki, D. Chaimala, I. Beltegris, P. Michalopoulou, G. Blazoyiannakis (Athens, Greece). The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC). Eur Respir J 2004; 24: Suppl. 48, 4100

Member's Comments

No comment yet.

Related content which might interest you: Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Benefit of immune checkpoint inhibitors (ICIs) for second-line treatment of advanced non-small cell lung cancer (NSCLC) using restricted mean survival time (RMST). Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Compassionate-use gefitinib in non–small cell lung cancer (NSCLC): results from a US expanded access program (EAP) Source: Eur Respir J 2004; 24: Suppl. 48, 231s Year: 2004 Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Early concurrent chemoradiotherapy for limited small cell lung cancer (LSCLC). Analysis of toxicity and survival of 30 consecutive patients Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002 Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 The comparison of paclitaxel-carboplatin (PCp) versus gemcitabine-cisplatin (GC) in the treatment of locally advanced or metastatic non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed (Pem) for advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 The results of gefitinib (Iressa) treatment in 89 patients with advanced non-small cell lung cancer (NSCLC) on expanded access programme (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 753s Year: 2006 Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010